Amylx Pharmaceuticals Inc vs JPMorgan Chase & Co — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while JPMorgan Chase & Co trades at $362.5 (market cap $956.39B). The key difference: JPMorgan Chase & Co is far larger — about 378× Amylx Pharmaceuticals Inc's market cap, and JPMorgan Chase & Co pays a 1.67% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | JPM | |
|---|---|---|
Market Cap | $2.53B | $956.39B |
Sector | Health | Financials |
52-Week High | $24.19 | $362.04 |
52-Week Low | $7.82 | $282.84 |
Enterprise Value | $2.28B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.67% |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, near its pivot point of $359. The stock shows a bullish technical trend with moving averages supporting upside. Recent earnings beat expectations in Q1 and Q2 2026, with Q1 EPS of $5.94 versus $5.47 expected, though Q4 2025 missed. Revenue grew to $181.85B in 2025, and net income margin stands at 33.38%. A $1.50 dividend is scheduled for payment on July 31, 2026.
JPMorgan's outlook remains positive with analyst consensus at 'Moderate Buy' and a $374.18 price target, offering ~4% upside. Strong ROE of 18.43% and institutional accumulation highlight confidence. Risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI, as noted in recent news. The stock's valuation at P/E 15.42 is reasonable relative to earnings growth potential.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →